IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, ...

The Democrats’ funding bill makes Americans unhealthy again

Radicals on the Left have no intention of making Americans healthy again, and their spending bill reflects it.

Should the UK introduce targeted prostate cancer screening? The case for and against

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.